The United Kingdom and the United States have signed a major commercial pact that will preserve no import taxes on British pharmaceutical exports being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise funding on drugs through the public health system. This commitment secures that import taxes on these vital goods will stay at nothing for a period of three years.
This agreement follows earlier threats to significantly raise import taxes on patented pharmaceutical imports, with increases discussed as high as double the cost.
"This arrangement between the Britain strengthens the global environment for cutting-edge drugs and introduces long-overdue equity to transatlantic drug exports," a release noted.
Trade Significance
Drugs represent one of the the United Kingdom's most significant export categories to the US, which is by far the biggest destination for major British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to September, the UK exported medicines worth over eleven billion pounds to the US. This figure represented 17.4% of British export trade in that span.
"This agreement secures work, increases investment and paves the way for the UK to become a international leader for medical research," a minister commented.
Key UK Commitments
The pact entails several notable changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to raise overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates were more than 20%.
Recent Tensions
The deal comes amid a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were intensified by arguments that US customers were paying a premium for the same drugs than people in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its resources over the previous ten-year period.
